Moderna Surges Amid Hantavirus Vaccine Research and mRNA Flu Vaccine Success
Moderna's stock price surged following the confirmation of its hantavirus vaccine research. The company's mRNA-based seasonal flu vaccine also showed promising results in a peer-reviewed trial. Moderna has collaborated with the U.S. Army and Korea University on the hantavirus vaccine since 2023.
Moderna's stock rose significantly following the announcement of its ongoing research collaboration with the U.S. Army and Korea University on a hantavirus vaccine. The initiative marks the start of this partnership in 2023.
In a separate development, Moderna's mRNA-based seasonal flu vaccine demonstrated superior efficacy in a peer-reviewed trial. The publication of these trial results contributed to the surge in the company's stock price.
While the hantavirus vaccine research and flu vaccine success may have driven investor enthusiasm, Novavax also saw a 13.16% increase in stock value on the back of Moderna's momentum and a strong Q1 2025 report, posting $139.51 million in sales and a net loss of $9 million .
Related Stocks
Powered by SentiSense - Intelligent Market Analysis